Westpac Banking Corp Alkermes Plc. Transaction History

Westpac Banking Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 11, 2020	SELL	$17.29 - $21.74 $160,001 - $201,181	-9,254 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$19.51 - $24.28 $180,545 - $224,687	9,254 New	9,254 $180,000
Q1 2019 May 14, 2019	SELL	$28.4 - $36.49 $262,813 - $337,678	-9,254 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$27.94 - $44.61 $258,556 - $412,820	9,254 New	9,254 $273,000
Q4 2017 Jan 18, 2018	SELL	$47.69 - $55.39 $441,323 - $512,579	-9,254 Closed	0 $0
Q3 2017 Oct 30, 2017	BUY	$49.16 - $54.45 $454,926 - $503,880	9,254	9,254 $0

386

166M

231K

158K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.57B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Westpac Banking Corp, based on Form 13F filings with the SEC.

Stay updated on Westpac Banking Corp with notifications on news.